AMGN
AMGEN INC
Nasdaq: AMGN · Thousand Oaks, CA · Healthcare
$437.23-6.89 (-1.55%)Closed
Market Cap$236.37B
Cash$13.99Bmost recent
Runwayprofitable
P/E (TTM)30.7EPS $14.23
52-Wk Range$263.86 – $444.12
Avg Volume2.7M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$437.23+43.2%
Pipeline

Drug candidates sponsored by AMGEN · ClinicalTrials.gov

71 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4cinacalcet
Chronic Kidney Disease+12 more
Completed
2011-12past
3
Phase 4Etanercept via Autoinjector A
Rheumatoid Arthritis+1 more
Completed
2014-03-04past
1
Phase 4evolocumab
Homozygous Familial Hypercholesterolemia HoFH+5 more
Completed
2020-09-02past
6
Phase 4Erenumab
Migraine
Completed
2023-09-28past
1
Phase 4romiplostim
Thrombocytopenia+6 more
Completed
2025-02-25past
3
Phase 4Avacopan
Antineutrophil Cytoplasmic Antibody-associated Vasculitis+1 more
Recruiting
2036-12-31
2
Phase 4Enbrel®
Psoriasis
Completed—1
Phase 3Darbepoetin alfa - 2.25 mcg/kg
Anemia+1 more
Completed
2004-12past
1
Phase 3Oxaliplatin Based Chemotherapy
Colorectal Cancer
Completed
2007-05-31past
1
Phase 3alendronate
Postmenopausal Osteoporosis
Completed
2008-03past
1
Phase 3Darbepoetin Alfa
Kidney Disease+5 more
Completed
2008-12past
5
Phase 3Actonel®
Osteoporosis
Completed
2011-12-21past
1
Phase 3HPN-100
Urea Cycle Disorders+2 more
Completed
2012-04past
2
Phase 3interferon γ-1b
Friedreich's Ataxia
Completed
2017-03-31past
1
Phase 3Cysteamine Bitartrate Delayed-release Capsules
Cystinosis
Completed
2017-06-26past
1
Phase 3Placebo
Breast Cancer+4 more
Completed
2017-08-31past
5
Phase 3Romosozumab
Postmenopausal Osteoporosis+1 more
Completed
2018-02-12past
2
Phase 3ABP 798
Lymphoma, Non-Hodgkin
Completed
2019-06-28past
1
Phase 3ABP 654
Plaque Psoriasis
Completed
2022-01-13past
1
Phase 3ABP 938
Chorioretinal Vascular Disease
Completed
2023-02-17past
1
Phase 3Erenumab Dose 1
Migraine
Completed
2025-01-08past
1
Phase 3ABP 234
Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Active, not recruiting
2026-12-14
1
Phase 3Maridebart cafraglutide
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight+2 more
Active, not recruiting
2027-01-21
2
Phase 3Inebilizumab
Autoimmune Hepatitis+2 more
Recruiting
2027-04-13
2
Phase 3Blinatumomab
Acute Lymphoblastic Leukemia+1 more
Active, not recruiting
2027-11-24
3
Phase 3Etelcalcetide
Secondary Hyperparathyroidism+1 more
Recruiting
2029-01-31
1
Phase 2Darbepoetin alfa SC
Anemia+1 more
Completed
2002-12past
1
Phase 2100 mg AMG 162
Osteoporosis
Completed
2007-06past
1
Phase 2Bevacizumab
Advanced Non-squamous NSCLC
Terminated
2008-04-23past
1
Phase 2AMG 951 (rhApo2L/TRAIL)
Non-Small Cell Lung Cancer
Completed
2009-03past
1
Phase 2Apremilast (CC-10004)
Behcet Syndrome
Completed
2012-05-01past
1
Phase 2CC-11050
Cutaneous Lupus Erythematosus
Completed
2013-01-01past
1
Phase 1Panitumumab
Lung Cancer+2 more
Completed
2015-03past
2
Phase 1oprozomib
Multiple Myeloma+1 more
Terminated
2016-08-08past
1
Phase 2Talimogene laherparepvec
Melanoma
Completed
2021-08-19past
1
Phase 2VIB4920
Sjögren's Syndrome
Completed
2022-09-01past
1
Phase 2Daxdilimab
Alopecia Areata
Completed
2023-08-07past
1
Phase 1Acapatamab
Metastatic Castration-resistant Prostate Cancer
Terminated
2023-10-23past
1
Phase 1sotorasib
KRAS p.G12C Mutant Advanced Solid Tumors
Completed
2026-05-29past
1
Phase 2Tarlatamab
Extensive Stage Small Cell Lung Cancer+2 more
Recruiting
2027-04-24
4
Phase 2pegfilgrastim
Breast Cancer+2 more
Completed—1
Phase 2ABX-EGF
Colorectal Cancer
Completed—1
Phase 1panitumumab (ABX-EGF)
Tumors+2 more
Completed
2006-04past
1
Phase 1AMG 706
Lung Cancer+2 more
Terminated
2007-06past
1
Phase 1MP-376 (Levofloxacin solution for Inhalation)
Chronic Obstructive Pulmonary Disease+1 more
Completed
2009-12past
2
Phase 1AMG811
Cutaneous Lupus+3 more
Terminated
2012-09past
1
Phase 1AMG 876
Diabetes Mellitus
Terminated
2014-11past
1
Phase 1ABP 501
Healthy Volunteers
Completed
2015-12-04past
1
Phase 1Etanercept
Postmenopausal+3 more
Terminated
2016-01past
1
Phase 1Carfilzomib
Multiple Myeloma
Completed
2016-03past
1
Phase 1AMG 211
GI Adenocarcinoma
Terminated
2017-11-06past
1
Phase 1FPA144
Gastric or Gastroesophageal Cancer
Completed
2018-06-19past
1
Phase 1AMG 224
Multiple Myeloma
Completed
2018-11-30past
1
Phase 1Rosuvastatin
Healthy Participants
Completed
2021-10-10past
1
Phase 1ABP 501-HCF
Adalimumab
Completed
2021-11-24past
1
Phase 1AMG 199
MUC17-positive Solid Tumors
Terminated
2023-06-01past
1
Phase 1VIB1116
Dendritic Cell -Mediated Rheumatic Diseases
Completed
2023-07-03past
1
Phase 1AMG 340
Metastatic Castration-resistant Prostate Cancer
Terminated
2024-06-24past
1
Phase 1AMG 119
Small Cell Lung Cancer
Suspended
2028-01-14
1
Phase 1AMG 436
Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Recruiting
2028-07-28
1
Phase 1YL201
Small Cell Lung Cancer
Active, not recruiting
2031-06-23
1
Phase 1AMG 386
Tumors
Completed—1
Early Phase 1Metoprolol
Atopic Dermatitis
Completed
2024-08-28past
1
N/AUnnamed
Breast Cancer+3 more
Completed
2009-10past
1
N/AUnnamed
Chemotherapy-induced Febrile Neutropenia
Completed
2016-10-28past
1
N/AUnnamed
Metastatic Colorectal Cancer
Completed
2018-08-03past
1
N/AUnnamed
Osteonecrosis of the Jaw+1 more
Completed
2019-08-05past
1
N/AUnnamed
ASCVD
Terminated
2020-12-21past
1
N/AUnnamed
RAS Wild Type mCRC
Completed
2021-05-31past
1
N/AUnnamed
Psoriasis
Completed
2021-10-27past
1
N/AUnnamed
Major Cardiovascular Event+1 more
Active, not recruiting
2028-12-19
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.